Bilayer Vaginal Ring for Progesterone Sustained Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaginal progesterone delivery systems for luteal support face issues such as hepatic first-pass effect, allergic reactions, poor patient compliance due to frequent administration, and environmental concerns from non-degradable materials, along with initial burst release and variable drug delivery.
Innovation Solution
A bilayer vaginal ring with a core layer of micronized progesterone dispersed in medical EVA and a film layer of EVA, providing a constant and slow drug release, avoiding burst release and improving patient compliance, while being more cost-effective and environmentally friendly.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If silicone rubber elastomer is used as carrier material in vaginal ring, then good biocompatibility and biological tolerance are achieved, but complex manufacturing process with high cost and non-degradability occur
Solution Approach 1:
The patent changes the material parameter from silicone rubber elastomer to medical-grade EVA (ethylene-vinyl acetate copolymer), which maintains biocompatibility while enabling simpler manufacturing processes and environmental degradability. This parameter substitution resolves the contradiction between reliability and device complexity.
2Reliability
If integrated progesterone-containing vaginal ring is used, then luteal support is provided, but initial burst release occurs causing adverse reactions
Solution Approach 1:
The patent segments the vaginal ring into a bilayer structure: an inner drug-loaded matrix layer containing micronized progesterone dispersed in EVA, and an outer drug-free film layer. This segmentation controls drug release by preventing initial burst release while maintaining sustained luteal support efficacy.
Solution Approach 2:
The patent uses composite materials by combining drug-loaded EVA matrix with drug-free EVA film in a bilayer configuration. The composite structure provides controlled drug release properties, eliminating the harmful initial burst release while preserving therapeutic efficacy.
3Reliability
If vaginal gel is used for progesterone delivery, then hepatic first pass effect is bypassed, but frequent administration and vaginal excretion staining occur
Solution Approach 1:
The patent employs a disposable vaginal ring that is inserted once and remains in place for extended periods (typically 14-28 days), providing continuous drug delivery. This eliminates the need for frequent administrations required by vaginal gels while maintaining high bioavailability by bypassing hepatic first-pass metabolism.
4Reliability
If progesterone injection is used, then definite efficacy and avoidance of hepatic first pass effect are achieved, but local or systemic allergic reaction and poor patient compliance occur
Solution Approach 1:
The patent replaces the mechanical injection system with a passive diffusion-based vaginal ring system. The ring delivers progesterone through controlled diffusion across the vaginal mucosa, eliminating the need for needles and oil-based solutions that cause allergic reactions, while maintaining definite therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system achieves a stable and prolonged release of progesterone, enhancing bioavailability and patient comfort, reducing side effects and environmental impact, with improved therapeutic efficacy and compliance compared to existing matrix-type vaginal rings.
Implementation Method 1
the core layer is composed of a solid scaffold carrier of medical EVA containing a uniformly dispersed (or dissolved) drug
Data Source
AI summary
The present invention relates to a vaginal sustained-release drug delivery system for luteal support and a method for preparation and use thereof. The vaginal sustained-release drug delivery system for luteal support is a progesterone depot-type vaginal ring having a bilayer structure of a core layer and a film layer enclosing the core layer, wherein the core layer is composed of a solid scaffold carrier of medical EVA containing a drug uniformly dispersed therein, and the film layer is composed of a medical EVA material containing no drug. The vaginal sustained-release drug delivery system for luteal support according to the present invention can be used for assisted reproduction and for treatment of functional uterine bleeding, premenstrual syndrome and the like due to luteal phase defect with a significantly improved therapeutic effect.